Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

510.38
-5.0800-0.99%
Post-market: 513.002.62+0.51%16:26 EDT
Volume:536.22K
Turnover:273.89M
Market Cap:21.89B
PE:18.26
High:515.55
Open:510.95
Low:507.03
Close:515.46
52wk High:609.35
52wk Low:375.61
Shares:42.89M
Float Shares:39.35M
Volume Ratio:1.27
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.42
PE(LYR):18.32

Loading ...

United Therapeutics Corporation Announces FDA Clearance to Proceed With Uheart Xenotransplantation Clinical Trial

THOMSON REUTERS
·
May 16

United Therapeutics CEO Martine Rothblatt disposes of USD 6.96 million in shares

Reuters
·
May 16

United Therapeutics CFO James Edgemond sells 9,000 shares for $5,162,421.22

Reuters
·
May 16

United Therapeutics, Varda to Study Space-Based Drug Manufacturing for Pulmonary Disease Treatments

MT Newswires Live
·
May 13

Varda Space Industries and United Therapeutics Collaborate to Advance Microgravity-Enabled Treatments for Rare Pulmonary Disease

THOMSON REUTERS
·
May 13

United Therapeutics CEO Martine Rothblatt sells USD 2.66 million in shares

Reuters
·
May 13

United Therapeutics CFO James Edgemond sells USD 5.74 million common shares

Reuters
·
May 13

United Therapeutics CFO presents at RBC Capital Markets Global Healthcare Conference

Reuters
·
May 12

United Therapeutics CFO James Edgemond sells common shares worth $4.17 million

Reuters
·
May 11

United Therapeutics CEO Martine Rothblatt disposes of 8,225 shares for $4.78 million

Reuters
·
May 11

United Therapeutics to present positive data of treprostinil in IPF

TIPRANKS
·
May 11

United Therapeutics presents Phase 3 ADVANCE OUTCOMES ralinepag PAH trial data at ATS 2026

Reuters
·
May 11

Assessing United Therapeutics (UTHR) Valuation After A Strong Year Of Shareholder Returns

Simply Wall St.
·
May 10

United Therapeutics EVP, General Counsel Paul Mahon disposes 8,300 shares for $4.86 million

Reuters
·
May 08

United Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 08

United Therapeutics Growth Outlook Remains Supported by Tyvaso, Ralinepag, RBC Says

MT Newswires Live
·
May 08

RBC Capital Adjusts United Therapeutics Price Target to $701 From $707, Maintains Outperform Rating

MT Newswires Live
·
May 07

United Therapeutics Raised to Overweight From Equal-Weight by Wells Fargo

Dow Jones
·
May 07

BUZZ-MannKind falls after quarterly revenue miss

Reuters
·
May 07

Morgan Stanley Trims Price Target on United Therapeutics to $516 From $519, Keeps Equalweight Rating

MT Newswires Live
·
May 07